Pay in 4 interest-free payments of $6.22 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Growth hormone-releasing hormone and growth hormone-releasing peptide as therapeutic agents to enhance growth hormone secretion in disease and aging
For liver diseases (treatment cycle is generally 30 days): Viral hepatitis: 1.2 grams intravenous injection per day for 30 days
437,438 This involves modulating the cell apoptosis process, for example, by decreasing the Bax/Bcl-2 ratio in cardiomyocytes, reducing cytochrome C release, and caspase activation
The schedule followed two key acceptance phases: February 2025 Project launch February 2026 Acceptance 1 (86%), followed by an additional tenweek period for testing and adjustments May 2026 Acceptance 2 (14%), followed by the final tenweek window before full delivery These periods covered FAT, integration work, documentation finalisation and site readiness to ensure seamless transition to commissioning activities
